title: Pleiotrophin, a candidate gene for poor tumor vasculature and in vivo neuroblastoma sensitivity to irinotecan.
abstract: In vivo neuroblastoma (NB) xenograft model, resistant to the DNA-topoisomerase I inhibitor irinotecan (CPT-11), has been established to study resistance mechanisms acquired in a therapeutic setting. Common mechanisms of resistance were not involved in this resistance. Thus, we compared the gene expression profiles of sensitive, resistant, and reverted tumors using cDNA expression arrays. Expression of selected transcripts was confirmed by quantitative real-time PCR. We found that pleiotrophin (PTN), a heparin-binding growth factor, was the only gene significantly affected: PTN gene expression was downregulated in all resistant tumors (8-14-fold) as compared to sensitive tumors, and was increased (2-4-fold) in all reverted tumors as compared to resistant tumors. PTN thus appeared to be a likely candidate gene associated with resistance to CPT-11 in this in vivo model. To investigate the direct implication of PTN in NB, we transfected two NB cell lines with RNA interferences in order to silence PTN. PTN failed to demonstrate implication in resistance to CPT-11 in vitro but could influence sensitivity to CPT-11 exclusively through an in vivo mechanism. Indeed, vasculature was significantly enhanced in resistant NB xenografts compared to sensitive and reverted xenografts, and we suggest that PTN is acting in our resistant in vivo NB model as an angiostatic factor.
authors.affiliation: Pharmacology and New Treatments of Cancer: UPRES-EA, 3535 Institut Gustave Roussy, Villejuif, France.
authors.forename: L
authors.initials: L
authors.lastname: Calvet
authors.forename: B
authors.initials: B
authors.lastname: Geoerger
authors.forename: M
authors.initials: M
authors.lastname: Regairaz
authors.forename: P
authors.initials: P
authors.lastname: Opolon
authors.forename: L
authors.initials: L
authors.lastname: Machet
authors.forename: J
authors.initials: J
authors.lastname: Morizet
authors.forename: J-M
authors.initials: JM
authors.lastname: Joseph
authors.forename: N
authors.initials: N
authors.lastname: Elie
authors.forename: G
authors.initials: G
authors.lastname: Vassal
mesh_terms: D000818:Animals; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002352:Carrier Proteins / Q000037:antagonists & inhibitors / Q000235:genetics*; D002675:Child, Preschool; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000235:genetics*; D019008:Drug Resistance, Neoplasm; D020869:Gene Expression Profiling; D005786:Gene Expression Regulation; D006801:Humans; D000077146:Irinotecan; D008297:Male; D051379:Mice; D009389:Neovascularization, Pathologic / Q000209:etiology*; D009447:Neuroblastoma / Q000098:blood supply / Q000188:drug therapy* / Q000235:genetics; D020411:Oligonucleotide Array Sequence Analysis; D012333:RNA, Messenger / Q000378:metabolism; D034741:RNA, Small Interfering / Q000494:pharmacology; D020133:Reverse Transcriptase Polymerase Chain Reaction; D059004:Topoisomerase I Inhibitors; D014407:Tumor Cells, Cultured; D023041:Xenograft Model Antitumor Assays
chemical_list: D002352:Carrier Proteins; D016207:Cytokines; D012333:RNA, Messenger; D034741:RNA, Small Interfering; D059004:Topoisomerase I Inhibitors; C066845:pleiotrophin; D000077146:Irinotecan; D002166:Camptothecin